Marksans Pharma Ltd
Marksans Pharma Ltd Share Price Today: Live Updates & Key Insights
Get insights on Marksans Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Marksans Pharma Ltd Share Price Chart
MARKSANS at 10 Jul 2026 05:18 PM Pharmaceuticals
272.40 -4.90(-1.77%)
Lowest Today 270.10
Highest Today 281.10
Today's Open 279.50
Prev. Close 277.30
52 Week High 281.60
52 Week Low 155.00
Marksans Pharma Ltd Fundamentals
Traded Volume: 21,92,697
Market Cap(Cr): 12,344.18
Avg Traded Price 273.54
1 Year return 5.23%
Upper Circuit 281.1
Lower Circuit 270.1
P/E TTM 30.00
P/B Ratio 4.157
Traded Value(Cr) 5972.91
EPS TTM 9.222
Book value/Share 66.710
Dividend Yield 1Y 0.29%
Marksans Pharma Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Marksans Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Marksans Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +1.95%
1M +7.77%
3M +55.67%
1Y +5.23%
YTD +54.17%
Marksans Pharma Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Marksans Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 45.52L
Day Before Yesterday 37.91L
1W Avg 25.14L
1M Avg 25.46L
3M Avg 31.13L
Marksans Pharma Ltd Technical Details
Marksans Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 267
Support 2 256
Support 3 249
Pivot Point : 274
Resistance 1 285
Resistance 2 292
Resistance 3 303
Marksans Pharma Ltd Corporate Actions
Marksans Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Marksans Pharma Ltd’s capital allocation strategies.
All
Ex-Date 01-Aug-2025 Type D Description 0.80/share@80.00% Record Date 01-Aug-2025 Ratio 80.00
Ex-Date 17-Sep-2024 Type D Description 0.60/share@60.00% Record Date 17-Sep-2024 Ratio 60.00
Ex-Date 07-Jun-2023 Type D Description 0.50/share@50.00% Record Date 07-Jun-2023 Ratio 50.00
Ex-Date 19-Aug-2022 Type D Description 0.25/share@25.00% Record Date - Ratio 25.00
Ex-Date 15-Sep-2021 Type D Description 0.25/share@25.00% Record Date - Ratio 25.00
Ex-Date 22-Sep-2020 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 19-Sep-2019 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 19-Sep-2018 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 19-Sep-2017 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 22-Sep-2016 Type D Description 0.12/share@12.00% Record Date - Ratio 12.00
Ex-Date 23-Sep-2015 Type D Description 0.12/share@12.00% Record Date - Ratio 12.00
Ex-Date 18-Sep-2014 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 11-Mar-2008 Type S Description share@1:10.00 Record Date 18-Mar-2008 Ratio 1:10.00
Dividends
Announcement Date 01-Aug-2025 Ex Dividend Date 01-Aug-2025 Dividend(%) 80
Announcement Date 17-Sep-2024 Ex Dividend Date 17-Sep-2024 Dividend(%) 60
Announcement Date 07-Jun-2023 Ex Dividend Date 07-Jun-2023 Dividend(%) 50
Announcement Date 19-Aug-2022 Ex Dividend Date 19-Aug-2022 Dividend(%) 25
Announcement Date 15-Sep-2021 Ex Dividend Date 15-Sep-2021 Dividend(%) 25
Announcement Date 22-Sep-2020 Ex Dividend Date 22-Sep-2020 Dividend(%) 10
Announcement Date 19-Sep-2019 Ex Dividend Date 19-Sep-2019 Dividend(%) 5
Announcement Date 19-Sep-2018 Ex Dividend Date 19-Sep-2018 Dividend(%) 5
Announcement Date 19-Sep-2017 Ex Dividend Date 19-Sep-2017 Dividend(%) 5
Announcement Date 22-Sep-2016 Ex Dividend Date 22-Sep-2016 Dividend(%) 12
Announcement Date 23-Sep-2015 Ex Dividend Date 23-Sep-2015 Dividend(%) 12
Announcement Date 18-Sep-2014 Ex Dividend Date 18-Sep-2014 Dividend(%) 10
Bonus
No Bonus has been declared by MARKSANS
Splits
Record Date 18-Mar-2008 Split Date 11-Mar-2008 Face Value (Before/After) 10.00/1.00
Others
Rights No Rights has been declared by MARKSANS
Marksans Pharma Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Marksans Pharma Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Marksans Pharma Ltd's relative performance and valuation against major competitors.
Stock Name Alivus Life Sciences Ltd ₹1160.10 (+1.50%) M. Cap (Cr) 142.39 1 Yr Return (%) +15.74% P/E (TTM) 25.22 PB Ratio 4.27
Stock Name Corona Remedies Ltd ₹2042.80 (+0.99%) M. Cap (Cr) 124.94 1 Yr Return (%) NaN% P/E (TTM) 67.49 PB Ratio 16.73
Stock Name Shilpa Medicare Ltd ₹627.15 (+0.78%) M. Cap (Cr) 122.66 1 Yr Return (%) +47.84% P/E (TTM) 50.41 PB Ratio 4.73
Stock Name Marksans Pharma Ltd ₹272.40 (-1.77%) M. Cap (Cr) 123.44 1 Yr Return (%) +5.23% P/E (TTM) 29.54 PB Ratio 4.08
Stock Name Viyash Scientific Ltd ₹277.80 (-1.16%) M. Cap (Cr) 121.36 1 Yr Return (%) +49.94% P/E (TTM) 101.48 PB Ratio 4.17
Stock Name Procter & Gamble Health Ltd ₹6839.00 (+3.43%) M. Cap (Cr) 113.52 1 Yr Return (%) +20.13% P/E (TTM) 34.73 PB Ratio 21.64
Stock Name Akums Drugs & Pharmaceuticals Ltd ₹701.95 (+6.65%) M. Cap (Cr) 110.48 1 Yr Return (%) +24.96% P/E (TTM) 43.29 PB Ratio 3.33
Marksans Pharma Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Marksans Pharma Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 211.09 Mar 2025 31.02 Mar 2024 34.05 Mar 2023 51.72 Mar 2022 50.97
PARTICULARS Investing Activities Mar 2026 -140.29 Mar 2025 17.24 Mar 2024 -114.22 Mar 2023 -194.62 Mar 2022 -8.40
PARTICULARS Financing Activities Mar 2026 -39.23 Mar 2025 -29.92 Mar 2024 -26.22 Mar 2023 210.02 Mar 2022 75.86
PARTICULARS Net Cash Flow Mar 2026 30.98 Mar 2025 18.34 Mar 2024 -106.38 Mar 2023 67.12 Mar 2022 118.44
Marksans Pharma Ltd Shareholding Pattern
This shows the ownership breakdown of Marksans Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 43.87%
Public 32.78%
Other Institutions 1.91%
FII 16.76%
Mutual Funds 4.66%
About Marksans Pharma Ltd
Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. Access Healthcare for Medical Products LLC, a Dubai-based front-marketing and promotion company was acquired in June, 2022. In 2023-24, Company acquired the business unit of Tevapharm India Private Limited in Verna, Goa as a going concern via slump sale in April, 2023.
Chairman & Managing Director
Mark Saldanha
Registered office 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053
FAX :91-22-40012000
Background
Incorporation Year 1992
Face Value ₹1.00
Market Lot 1
FAQs on Marksans Pharma Ltd
How to buy Marksans Pharma Ltd shares?
To buy Marksans Pharma Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Marksans Pharma Ltd?
The company has a market capitalization of ₹12,344.18.
What is the PE & PB ratio of Marksans Pharma Ltd?
PE is 30 and PB is 4.157.
What is the Marksans Pharma Ltd dividend for 2025–26?
For the 2025–26 financial year, Marksans Pharma Ltd declared a final dividend of 0.29% per share.